CL2016003179A1 - El control efectivo y eficaz del fosfato sérico para una osificación óptima - Google Patents
El control efectivo y eficaz del fosfato sérico para una osificación óptimaInfo
- Publication number
- CL2016003179A1 CL2016003179A1 CL2016003179A CL2016003179A CL2016003179A1 CL 2016003179 A1 CL2016003179 A1 CL 2016003179A1 CL 2016003179 A CL2016003179 A CL 2016003179A CL 2016003179 A CL2016003179 A CL 2016003179A CL 2016003179 A1 CL2016003179 A1 CL 2016003179A1
- Authority
- CL
- Chile
- Prior art keywords
- effective
- ossification
- optimal
- serum phosphate
- effective control
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009474P | 2014-06-09 | 2014-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016003179A1 true CL2016003179A1 (es) | 2017-11-03 |
Family
ID=54769049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016003179A CL2016003179A1 (es) | 2014-06-09 | 2016-12-09 | El control efectivo y eficaz del fosfato sérico para una osificación óptima |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10639360B2 (https=) |
| EP (3) | EP3845245B1 (https=) |
| JP (2) | JP6808493B2 (https=) |
| KR (4) | KR102947335B1 (https=) |
| CN (1) | CN106604743A (https=) |
| AR (2) | AR100689A1 (https=) |
| AU (1) | AU2015275128C1 (https=) |
| BR (2) | BR112016028567A2 (https=) |
| CA (1) | CA2949234C (https=) |
| CL (1) | CL2016003179A1 (https=) |
| CY (1) | CY1124328T1 (https=) |
| DK (2) | DK3151859T3 (https=) |
| ES (2) | ES3040805T3 (https=) |
| FI (1) | FI3845245T3 (https=) |
| HR (2) | HRP20210250T1 (https=) |
| HU (2) | HUE053271T2 (https=) |
| LT (2) | LT3845245T (https=) |
| MX (2) | MX381052B (https=) |
| PE (1) | PE20170248A1 (https=) |
| PL (2) | PL3845245T3 (https=) |
| PT (2) | PT3845245T (https=) |
| RS (2) | RS61443B1 (https=) |
| SI (2) | SI3151859T1 (https=) |
| SM (2) | SMT202500342T1 (https=) |
| WO (1) | WO2015191312A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CN106709662B (zh) * | 2016-12-30 | 2021-07-02 | 山东鲁能软件技术有限公司 | 一种电力设备运行工况划分方法 |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| BR112021019337A2 (pt) * | 2019-03-29 | 2021-12-07 | Atarga Llc | Anticorpo anti-fgf23 |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| EP4676955A2 (en) * | 2023-03-10 | 2026-01-14 | Ultragenyx Pharmaceutical Inc. | Human fgf23-binding antibodies with improved affinity and efficacy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU2005202100A1 (en) | 1999-05-11 | 2005-06-09 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| ATE461213T1 (de) | 2000-07-19 | 2010-04-15 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
| EP2233571B1 (en) | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| JP4527982B2 (ja) * | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子−２３に対する抗体 |
| EP1833848A2 (en) * | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| US8158725B2 (en) | 2005-08-22 | 2012-04-17 | Bridgestone Corporation | Functionalized polymers and tires therefrom |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| US9982023B2 (en) * | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
-
2015
- 2015-05-29 MX MX2016016296A patent/MX381052B/es unknown
- 2015-05-29 CA CA2949234A patent/CA2949234C/en active Active
- 2015-05-29 SI SI201531522T patent/SI3151859T1/sl unknown
- 2015-05-29 BR BR112016028567A patent/BR112016028567A2/pt not_active Application Discontinuation
- 2015-05-29 KR KR1020247017683A patent/KR102947335B1/ko active Active
- 2015-05-29 WO PCT/US2015/033226 patent/WO2015191312A1/en not_active Ceased
- 2015-05-29 LT LTEP20208220.2T patent/LT3845245T/lt unknown
- 2015-05-29 ES ES20208220T patent/ES3040805T3/es active Active
- 2015-05-29 DK DK15806501.1T patent/DK3151859T3/da active
- 2015-05-29 PT PT202082202T patent/PT3845245T/pt unknown
- 2015-05-29 KR KR1020177000293A patent/KR20170013993A/ko not_active Ceased
- 2015-05-29 US US14/725,320 patent/US10639360B2/en active Active
- 2015-05-29 RS RS20210173A patent/RS61443B1/sr unknown
- 2015-05-29 LT LTEP15806501.1T patent/LT3151859T/lt unknown
- 2015-05-29 HR HRP20210250TT patent/HRP20210250T1/hr unknown
- 2015-05-29 KR KR1020217024284A patent/KR20210099180A/ko not_active Ceased
- 2015-05-29 HR HRP20251099TT patent/HRP20251099T1/hr unknown
- 2015-05-29 PE PE2016002698A patent/PE20170248A1/es unknown
- 2015-05-29 SM SM20250342T patent/SMT202500342T1/it unknown
- 2015-05-29 EP EP20208220.2A patent/EP3845245B1/en active Active
- 2015-05-29 EP EP25184948.5A patent/EP4647444A3/en active Pending
- 2015-05-29 FI FIEP20208220.2T patent/FI3845245T3/fi active
- 2015-05-29 ES ES15806501T patent/ES2851674T3/es active Active
- 2015-05-29 AR ARP150101715A patent/AR100689A1/es unknown
- 2015-05-29 BR BR122023023102-3A patent/BR122023023102A2/pt not_active Application Discontinuation
- 2015-05-29 PT PT158065011T patent/PT3151859T/pt unknown
- 2015-05-29 KR KR1020267009825A patent/KR20260051107A/ko active Pending
- 2015-05-29 AU AU2015275128A patent/AU2015275128C1/en active Active
- 2015-05-29 PL PL20208220.2T patent/PL3845245T3/pl unknown
- 2015-05-29 SM SM20210096T patent/SMT202100096T1/it unknown
- 2015-05-29 HU HUE15806501A patent/HUE053271T2/hu unknown
- 2015-05-29 JP JP2016569651A patent/JP6808493B2/ja active Active
- 2015-05-29 CN CN201580039280.XA patent/CN106604743A/zh active Pending
- 2015-05-29 SI SI201532076T patent/SI3845245T1/sl unknown
- 2015-05-29 HU HUE20208220A patent/HUE073105T2/hu unknown
- 2015-05-29 PL PL15806501T patent/PL3151859T3/pl unknown
- 2015-05-29 DK DK20208220.2T patent/DK3845245T3/da active
- 2015-05-29 RS RS20250889A patent/RS67294B1/sr unknown
- 2015-05-29 EP EP15806501.1A patent/EP3151859B1/en active Active
-
2016
- 2016-12-08 MX MX2021003740A patent/MX2021003740A/es unknown
- 2016-12-09 CL CL2016003179A patent/CL2016003179A1/es unknown
-
2020
- 2020-03-26 US US16/831,179 patent/US11202822B2/en active Active
- 2020-12-09 JP JP2020204298A patent/JP6993490B2/ja active Active
-
2021
- 2021-02-23 CY CY20211100154T patent/CY1124328T1/el unknown
- 2021-11-12 US US17/525,738 patent/US11771748B2/en active Active
-
2023
- 2023-08-07 US US18/366,447 patent/US12358976B2/en active Active
- 2023-11-14 AR ARP230103059A patent/AR131056A2/es unknown
-
2025
- 2025-06-11 US US19/235,347 patent/US20260035449A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003179A1 (es) | El control efectivo y eficaz del fosfato sérico para una osificación óptima | |
| BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| BR112015021999A8 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| GT201700035A (es) | Compuestos aminopirimidinilo como inhibidores de jak | |
| MX374452B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| GT201400034A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| BR112015032595A2 (pt) | inibidores de ido | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| BR112016029076A8 (pt) | Modulação de atividade de complemento | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| UY36448A (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
| MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| EA201890884A1 (ru) | Способ и композиции для нежелательных и аномальных мышечных сокращений | |
| CO2018013240A2 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
| BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
| BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
| UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. |